In a newly created role, the company is bringing on former MedReleaf Corporation vice president Ivan Latysh as chief technology officer.
Latysh will oversee and develop the execution of Flowr’s technology and data-driven strategies, the Toronto-based company said in a statement.
“The addition of Ivan to our executive leadership team will ensure our operations and commercialization initiatives are supported by the technology and data-driven strategies that are necessary to excel in today’s market,” Vinay Tolia, Flowr’s CEO said in a statement announcing the news.
“Enhancing our capabilities in this area are critical as we integrate our recent acquisition of operational footprints in Europe and Australia.”
In addition, the medical cannabis company appointed Laurence Levi as chief strategy officer and Francesco Tallarico as chief legal officer.
Both Levi and Tallarico served in leadership roles with Flowr as executive vice president and general counsel respectively.
“Laurence and Francesco are invaluable members of our executive leadership team and have been instrumental in helping us become a global cannabis company,” CEO Tolia said in a statement.
“With the recent acquisition of the Holigen medical cannabis brand, we are advancing our efforts for The Flowr Corporation to be a dominant player in the years to come.”
Flowr also announced that the board of directors of the company has approved the granting of 550,000 incentive stock options and aggregate of 760,000 restricted share units to certain officers of the company.
The options are exercisable at a price of either C$2.74 or C$2.88 per share for a five-year period.
The company also said that the board had approved an increase in the exercise price of 665,000 shares held by certain officers and directors from C$5.93 to C$6.98 and from C$5.70 to C$6.71.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas